

Yenal Dundar

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7107771/publications.pdf>

Version: 2024-02-01

43
papers

1,826
citations

304368

22
h-index

276539

41
g-index

43
all docs

43
docs citations

43
times ranked

2975
citing authors

#	ARTICLE	IF	CITATIONS
1	A systematic review of the research on communication between patients and health care professionals about medicines: the consequences for concordance. <i>Health Expectations</i> , 2004, 7, 235-245.	1.1	325
2	Comparative efficacy of newer hypnotic drugs for the short-term management of insomnia: a systematic review and meta-analysis. <i>Human Psychopharmacology</i> , 2004, 19, 305-322.	0.7	155
3	First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer. <i>The Cochrane Library</i> , 2016, , CD010383.	1.5	146
4	Drug-eluting stents: an early systematic review to inform policy*1, *2. <i>European Heart Journal</i> , 2004, 25, 902-919.	1.0	114
5	Cytochrome P450 testing for prescribing antipsychotics in adults with schizophrenia: systematic review and meta-analyses. <i>Pharmacogenomics Journal</i> , 2011, 11, 1-14.	0.9	99
6	Drug-eluting stents versus bare metal stents for angina or acute coronary syndromes. , 2010, , CDO04587.		64
7	Comparative efficacy of thrombolytics in acute myocardial infarction: a systematic review. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2003, 96, 103-113.	0.2	63
8	So many filters, so little time: the development of a search filter appraisal checklist. <i>Journal of the Medical Library Association: JMLA</i> , 2008, 96, 356-361.	0.6	62
9	The clinical effectiveness and cost-effectiveness of the PROGENSA® prostate cancer antigen 3 assay and the Prostate Health Index in the diagnosis of prostate cancer: a systematic review and economic evaluation. <i>Health Technology Assessment</i> , 2015, 19, 1-192.	1.3	58
10	Adverse events associated with intravenous iron infusion (low-molecular-weight iron dextran and) Tj ETQq0 0 0 rgBT (Overlock 10 Tf 50	0.2	49
11	Erlotinib Monotherapy for the Maintenance Treatment of Non-Small Cell Lung Cancer after Previous Platinum-Containing Chemotherapy. <i>Pharmacoeconomics</i> , 2011, 29, 1051-1062.	1.7	47
12	Cetuximab for Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck. <i>Pharmacoeconomics</i> , 2010, 28, 439-448.	1.7	45
13	A systematic review of the diagnostic accuracy of automated tests for cognitive impairment. <i>International Journal of Geriatric Psychiatry</i> , 2018, 33, 561-575.	1.3	41
14	A systematic review of lenvatinib and sorafenib for treating progressive, locally advanced or metastatic, differentiated thyroid cancer after treatment with radioactive iodine. <i>BMC Cancer</i> , 2019, 19, 1209.	1.1	38
15	Monozygotic twinning, cerebral palsy and congenital anomalies. <i>Human Reproduction Update</i> , 2009, 15, 639-648.	5.2	32
16	Pharmacological treatment of acute agitation associated with psychotic and bipolar disorder: a systematic review and meta-analysis. <i>Human Psychopharmacology</i> , 2016, 31, 268-285.	0.7	31
17	Biofeedback for hypertension: a systematic review. <i>Journal of Hypertension</i> , 2010, 28, 644-652.	0.3	30
18	Lenvatinib and sorafenib for differentiated thyroid cancer after radioactive iodine: a systematic review and economic evaluation. <i>Health Technology Assessment</i> , 2020, 24, 1-180.	1.3	29

#	ARTICLE	IF	CITATIONS
19	Moderators of the effect of psychological interventions on depression and anxiety in cardiac surgery patients: A systematic review and meta-analysis. Behaviour Research and Therapy, 2015, 73, 151-164.	1.6	28
20	Percutaneous transluminal coronary angioplasty with stents versus coronary artery bypass grafting for people with stable angina or acute coronary syndromes. The Cochrane Library, 2005, , CD004588.	1.5	27
21	A web resource for mining HLA associations with adverse drug reactions: HLA-ADR. Database: the Journal of Biological Databases and Curation, 2016, 2016, baw069.	1.4	24
22	Heated Humidified High-Flow Nasal Cannula for Preterm Infants: An Updated Systematic Review and Meta-analysis. International Journal of Technology Assessment in Health Care, 2019, 35, 298-306.	0.2	24
23	Rituximab for the First-Line Maintenance Treatment of Follicular Non-Hodgkin's Lymphoma. Pharmacoeconomics, 2013, 31, 403-413.	1.7	23
24	A scoping study to explore the cost-effectiveness of next-generation sequencing compared with traditional genetic testing for the diagnosis of learning disabilities in children. Health Technology Assessment, 2015, 19, 1-90.	1.3	23
25	The clinical effectiveness and cost-effectiveness of heated humidified high-flow nasal cannula compared with usual care for preterm infants: systematic review and economic evaluation. Health Technology Assessment, 2016, 20, 1-68.	1.3	22
26	Pertuzumab in Combination with Trastuzumab and Docetaxel for the Treatment of HER2-Positive Metastatic or Locally Recurrent Unresectable Breast Cancer. Pharmacoeconomics, 2015, 33, 13-23.	1.7	21
27	Erlotinib and gefitinib for treating non-small cell lung cancer that has progressed following prior chemotherapy (review of NICE technology appraisals 162 and 175): a systematic review and economic evaluation. Health Technology Assessment, 2015, 19, 1-134.	1.3	20
28	Angioplasty and stents in coronary artery disease: a systematic review and meta-analysis. Scandinavian Cardiovascular Journal, 2004, 38, 200-210.	0.4	19
29	Antiepileptic drugs as prophylaxis for postcraniotomy seizures. The Cochrane Library, 2018, 5, CD007286.	1.5	19
30	Allopurinol for the treatment of chronic kidney disease: a systematic review. Health Technology Assessment, 2014, 18, 1-77, v-vi.	1.3	19
31	Pemetrexed disodium in combination with cisplatin versus other cytotoxic agents or supportive care for the treatment of malignant pleural mesothelioma. , 2007, , CD005574.		17
32	Vemurafenib for the Treatment of Locally Advanced or Metastatic BRAF V600 Mutation-Positive Malignant Melanoma: A NICE Single Technology Appraisal. Pharmacoeconomics, 2013, 31, 1121-1129.	1.7	16
33	Eribulin for the Treatment of Advanced or Metastatic Breast Cancer: A NICE Single Technology Appraisal. Pharmacoeconomics, 2015, 33, 137-148.	1.7	16
34	Cenegermin for Treating Neurotrophic Keratitis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. Pharmacoeconomics - Open, 2019, 3, 453-461.	0.9	16
35	Superiority and equivalence in thrombolytic drugs: an interpretation. QJM - Monthly Journal of the Association of Physicians, 2003, 96, 155-160.	0.2	13
36	Antiepileptic drugs as prophylaxis for postcraniotomy seizures. The Cochrane Library, 2020, 4, CD007286.	1.5	12

#	ARTICLE	IF	CITATIONS
37	Case study of the comparison of data from conference abstracts and full-text articles in health technology assessment of rapidly evolving technologies: Does it make a difference?. International Journal of Technology Assessment in Health Care, 2006, 22, 288-294.	0.2	10
38	Dabrafenib for Treating Unresectable, Advanced or Metastatic BRAF V600 Mutation-Positive Melanoma: An Evidence Review Group Perspective. Pharmacoeconomics, 2015, 33, 893-904.	1.7	7
39	Automated tests for diagnosing and monitoring cognitive impairment: a diagnostic accuracy review. Health Technology Assessment, 2016, 20, 1-74.	1.3	6
40	Encorafenib with Binimetinib for the Treatment of Patients with BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. Pharmacoeconomics - Open, 2021, 5, 13-22.	0.9	5
41	Prasugrel (Efient®) with percutaneous coronary intervention for treating acute coronary syndromes (review of TA182): systematic review and economic analysis. Health Technology Assessment, 2015, 19, 1-130.	1.3	5
42	Searching for and use of conference abstracts in health technology assessments: Policy and practice. International Journal of Technology Assessment in Health Care, 2006, 22, 283-287.	0.2	4
43	Brentuximab Vedotin for Treating Relapsed or Refractory CD30-Positive Cutaneous T-Cell Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. Pharmacoeconomics - Open, 2020, 4, 563-574.	0.9	2